Eli Casdin & Keith Meister of CM Life Sciences, and Sema4 CEO, Eric Schadt, talked to CNBC about how their plans to go public will help them deliver on transforming clinical & life sciences through better leveraging of data.
CM Life Sciences announces combination with Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Accelerate Growth
As filed with the Securities and Exchange Commission
CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial Public Offering
Link to all items filed with the Securities and Exchange Commission